Report library

Vaccines Market Access in Emerging Markets

$3,000.00

Emerging markets account for approximately 18% of the global vaccines market, which is valued at more than $24bn. However, there are indications that this is an underestimate, and some observers forecast that the overall marketplace will reach $50bn by the mid2020s.

August 29, 2019

Januvia

Januvia (sitagliptin; Merck & Co) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.

Oncology Pathways in the US – Friend or Foe for Pharma

$7,500.00

This strategy report focuses on Oncology Pathways in the US including management of oncology costs, oncology clinical pathway programs and developers, impact of pathways on oncology, and the future of oncology pathways.

July 31, 2015

Japan Pricing and Reimbursement

Pricing and reimbursement processes are closely connected in Japan, with drug pricing largely dependent on innovation. However, achieving premium pricing is difficult, thereby limiting sales potential.

November 4, 2016

Ad26.RSV.preF

Ad26.RSV.preF, in development by Johnson & Johnson, is a replication-deficient vector vaccine that encodes a prefusion form of the RSV F protein.

October 5, 2018

SGLT-2 Pulse Survey

We surveyed primary care physicians (n=10) and endocrinologists (n=10) to see how SGLT-2 inhibitors and the combo pills will be used and what the potential impact of usage with GLP-1 agonists may have.

August 25, 2014

Tradjenta

Tradjenta (linagliptin; Boehringer Ingelheim/Eli Lilly) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut.

Humira

Humira (adalimumab; AbbVie/Eisai) is a recombinant human immunoglobulin G1 monoclonal antibody that acts as a tumor necrosis factor (TNF) inhibitor.

August 2, 2018

Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014–18

Immuno-oncology continues to draw pharma companies to the deal table.

August 5, 2019

Disease Analysis Atopic Dermatitis

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. The condition usually begins during early infancy and childhood, but can persist into, or start during, adulthood.

April 22, 2022

Neuromodulation: Spinal Cord Stimulation Devices Market

According to a recent CDC study, 20.1% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities with similar numbers being reported in Europe. In 2021, the spinal cord stimulation (SCS) devices market was worth nearly $2.9 bn. Market drivers of the SCS devices market through 2026 will be driven by an aging population and an increase in selected conditions (eg back/leg pain, and a growing number of indications) that result in debilitating and unrelenting chronic pain.

February 22, 2022

Rheumatoid Arthritis KOL Interview – New Jersey, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

July 31, 2019

Farletuzumab

Drug Overview Farletuzumab is a folate receptor alpha (FRa)-targeted monoclonal antibody being developed by Eisai. It is composed of grafted murine complementarity-determining regions on a human IgG1 kappa backbone. Inhibiting FRa can decrease cellular proliferation through inhibition of both Lyn kinase substrate phosphorylation and the interaction between Lyn tyrosine kinase and membrane signaling complexes; effectively […]

August 17, 2017

Global Diabetes Management Devices Market

The global market for diabetes management devices—valued at more than $9bn in 2015—is a substantial, highly competitive market driven by highly sophisticated, evolving technology, particularly in the insulin pump/artificial pancreas and CGM area.

March 30, 2017

Hip Replacement Implants Market

An aging global population and increasing life expectancy are driving growth in the global market for hip replacement implants. This market is expected to grow at a CAGR of 2.1% over the forecast period, reaching a value of nearly $7bn in the year 2024.

October 22, 2020

U.S. Markets for Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic oncology-related MRI and NMMI systems arena.

September 22, 2016

Treatment of VTE – US KOL Interview

This interview with a US hematologist focuses on the changing dynamics with the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

November 2, 2015

Idasanutlin

Idasanutlin (Roche) is an oral inhibitor of the murine double minute 2 (MDM2) protein, which blocks the interaction of MDM2 with the p53 tumor suppressor.

July 6, 2017

Follicular Lymphoma KOL Interview

“When people need therapy (for advanced stage Follicular Lymphoma), there’s a whole gamut. If they have relatively low volume disease, one option, which unfortunately in the community I would say is underutilized, is single-agent rituximab.”

February 3, 2016

Toujeo

Toujeo (insulin glargine U300) is a long-acting basal insulin analog based on Sanofi’s hugely successful Lantus (insulin glargine) for use in the treatment of type 1 and type 2 diabetes. The new product is a formulation which is three times more concentrated than the original, with a reduced volume and surface area of the subcutaneous depot.

Infection Control and Biosafety Products

A healthcare-associated infection (HAI) is any infection acquired in a clinic, hospital, long-term care
facility, or other healthcare delivery site.

July 12, 2019

Datamonitor Healthcare HIV KOL Interview – Germany

A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Alofisel

Alofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection.

August 2, 2018

Diagnostic Electrocardiograph Products

The global market for diagnostic electrocardiograph products is anticipated to see high, single-digit growth throughout the forecast period covered by this analysis (2017-22). Growth in unit sales is being driven by the increasing prevalence of cardiovascular disease, which is the leading cause of death globally, responsible for over 17 million deaths annually.

June 7, 2018

Zybrestat

Zybrestat (fosbretabulin tromethamine; Mateon Therapeutics) is a water-soluble prodrug of cis-combretastatin A4, originally isolated from the African bush willow (Combretum caffrum).

August 17, 2017

Italy, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries

December 3, 2012

Afrezza

Afrezza (inhaled human insulin; Sanofi) is a drug-device combination product consisting of an ultra-rapid-acting human insulin for oral inhalation, approved for use in the US for the treatment of type 1 and type 2 diabetes.

Aspirin

Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID) and antiplatelet that is taken orally and commonly used for the treatment of pain. It is highly genericized and has been available in its present form since 1899, when it was first marketed by Bayer.

July 2, 2018

Disease Analysis: Type 2 Diabetes

Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.

September 14, 2022

Indonesia Generics and Biosimilars

In 2011, branded generics accounted for 89% of Indonesia’s overall prescription pharmaceutical market, which was valued at IDR25.04tn ($2.84bn). The overwhelming dominance of generics – both branded and unbranded – leaves very little room for innovative products, other than those whose patents have already expired (i.e. “long-listed drugs”).

November 3, 2016

Neupro

Neupro (UCB/Otsuka) is a transdermal formulation of the non-ergoline dopamine receptor agonist rotigotine. Applied once daily, the patch allows continuous drug administration over 24 hours and avoids the fluctuation in dopaminergic stimulation resulting from numerous oral doses

June 21, 2018

Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

This report provides a detailed presentation of diabetes and blood glucose monitoring devices, including standard fingerstick-based blood glucose meters (BGMs) and new sensor-based continuous glucose monitoring systems (CGMs) that attach to the body and monitor blood glucose 24 hours a day

March 31, 2021

Lyrica

Lyrica (pregabalin; Pfizer/Eisai) is a gamma-aminobutyric acid alpha-2-delta subunit agonist, developed and launched by Pfizer (formerly Warner-Lambert) as the successor to Neurontin.

May 23, 2017

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US

An interview with a US key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine

November 19, 2018

ProstAtak

ProstAtak (AdV-tk + valacyclovir) is a viral cancer vaccine being developed by Advantagene for the treatment of prostate cancer. It works by gene-mediated cytotoxic immunotherapy, an approach that generates a tumor-specific vaccine.

September 24, 2015

Datamonitor Healthcare HIV KOL Interview – US #2

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

Valued at approximately $1.1bn in 2017, the implantable Deep Brain Stimulation (DBS) and Vagus Nerve Stimulation (VNS) Device Markets are two important and growing neuromodulation segments (outside of the largest, most dynamic $2.5bn segment, Spinal Cord Stimulation or SCS).

August 31, 2018

ChimeriVax-Dengue

ChimeriVax-Dengue (Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric LAVs.

October 28, 2015

Market Spotlight: Insomnia

$1,318.00

This Market Spotlight report covers the insomnia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

September 29, 2022

FluMist QIV

FluMist QIV (AstraZeneca/Daiichi Sankyo) is a quadrivalent live-attenuated influenza vaccine containing antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.

January 10, 2019

Key Trends in BRICMIST Market Access

Brazil, Russia, India, China, Mexico, Indonesia, South Korea, and Turkey – known collectively as the BRIC/MIST countries – have been a source of welcome growth for a pharmaceutical industry struggling to generate significant gains in its traditional core markets.

October 17, 2016

Ongentys

Ongentys (Neurocrine/Bial/Ono Pharmaceutical) is a once-daily formulation of the catechol-O-methyltransferase (COMT) inhibitor opicapone, approved as an add-on therapy to levodopa for the treatment of Parkinson’s disease patients with end-of-dose motor fluctuations.

June 21, 2018

Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy

In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Arikayce

Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and is under development for the treatment of lung infections caused by NTM.

September 3, 2018